J
James A. Retsema
Researcher at Pfizer
Publications - 40
Citations - 2863
James A. Retsema is an academic researcher from Pfizer. The author has contributed to research in topics: Azithromycin & Antibacterial agent. The author has an hindex of 20, co-authored 40 publications receiving 2808 citations. Previous affiliations of James A. Retsema include Yeshiva University.
Papers
More filters
Journal ArticleDOI
Pirbenicillin: Pharmacokinetic Parameters in Mice
TL;DR: Values suggest that the interchange of pirbenicillin between the central and peripheral body compartments of the mouse was slower than that of either carbenicisin or ampicillin and indicated that a greater fraction of the pirbeniillin than theAmpicillin dose reached the peripheral compartment.
Journal ArticleDOI
Activity of Sulbactam/Ampicillin in Screening and Discriminative Animal Models of Infection
TL;DR: Supportive pharmacokinetic studies demonstrated that sulbactam and ampicillin generally were delivered with equal efficiency to plasma and to extravascular fluids obtained by sampling the contents of implanted cylinders.
Journal ArticleDOI
Laboratory Evaluation of 3-(5-Tetrazolyl)Penam, a New Semisynthetic Beta-Lactam Antibacterial Agent with Extended Broad-Spectrum Activity
TL;DR: The new agent 3-(5-tetrazolyl)penam, hereafter referred to as CP-35,587, combines and extends the antibacterial activity of broad-spectrum penicillins and orally active cephalosporins.
Journal ArticleDOI
Susceptibility and resistance emergence studies with macrolides
TL;DR: Data from two types of in vitro susceptibility studies, an animal tissue infection model, and a clinical pediatric study demonstrate that prolonged tissue concentrations of azithromycin are unlikely to lead to the emergence of resistance in the clinical setting, and resistance to macrolides, and azithroitin in particular, is significantly over-estimated for bacterial strains incubated in the presence of CO2.
Journal ArticleDOI
(6R,8S)-(2-benzimidazolyl)hydroxymethylpenicillanic acids as potent antibacterial agents and beta-lactamase inhibitors.
Yuhpyng L. Chen,Kirk Hedberg,Karen J. Guarino,James A. Retsema,M Anderson,Mary Manousos,John F. Barrett +6 more
TL;DR: (6R,8S)-(2-Benzimidazolyl)hydroxymethylpenicillanic acids (1a-1x) are potent antibacterial agents and beta-lactamase inhibitors against Gram-positive bacteria and Haemophilus influenzae.